439 related articles for article (PubMed ID: 26003826)
1. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
Li S; Xu RX; Zhang Y; Guo YL; Zhu CG; Liu G; Dong Q; Li JJ
J Endocrinol Invest; 2015 Dec; 38(12):1291-9. PubMed ID: 26003826
[TBL] [Abstract][Full Text] [Related]
2. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
[TBL] [Abstract][Full Text] [Related]
3. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects.
Kwakernaak AJ; Lambert G; Dullaart RP
Clin Biochem; 2012 Nov; 45(16-17):1522-4. PubMed ID: 22809551
[TBL] [Abstract][Full Text] [Related]
4. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease.
Li S; Guo YL; Xu RX; Zhang Y; Zhu CG; Sun J; Qing P; Wu NQ; Jiang LX; Li JJ
Atherosclerosis; 2014 Jun; 234(2):441-5. PubMed ID: 24769476
[TBL] [Abstract][Full Text] [Related]
5. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
Zhang Y; Xu RX; Li S; Zhu CG; Guo YL; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):426-33. PubMed ID: 25770756
[TBL] [Abstract][Full Text] [Related]
6. Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease.
Li S; Zhang Y; Xu RX; Guo YL; Zhu CG; Wu NQ; Qing P; Liu G; Dong Q; Li JJ
Ann Med; 2015; 47(5):386-93. PubMed ID: 26153823
[TBL] [Abstract][Full Text] [Related]
7. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease.
Zhang Y; Zhu CG; Xu RX; Li S; Guo YL; Sun J; Li JJ
J Clin Lipidol; 2014; 8(5):494-500. PubMed ID: 25234562
[TBL] [Abstract][Full Text] [Related]
8. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
[TBL] [Abstract][Full Text] [Related]
9. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
Zhu YM; Anderson TJ; Sikdar K; Fung M; McQueen MJ; Lonn EM; Verma S
Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2254-9. PubMed ID: 26293463
[TBL] [Abstract][Full Text] [Related]
10. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease.
Xu RX; Li S; Zhang Y; Li XL; Guo YL; Zhu CG; Li JJ
Lipids Health Dis; 2014 Dec; 13():188. PubMed ID: 25496400
[TBL] [Abstract][Full Text] [Related]
11. The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease.
Li S; Zhu CG; Guo YL; Xu RX; Zhang Y; Sun J; Li JJ
J Atheroscler Thromb; 2015; 22(1):76-84. PubMed ID: 25185779
[TBL] [Abstract][Full Text] [Related]
12. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
[TBL] [Abstract][Full Text] [Related]
13. Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A Prospective Observational Cohort Study.
Li JJ; Li S; Zhang Y; Xu RX; Guo YL; Zhu CG; Wu NQ; Qing P; Gao Y; Sun J; Liu G; Dong Q
Medicine (Baltimore); 2015 Dec; 94(52):e2426. PubMed ID: 26717403
[TBL] [Abstract][Full Text] [Related]
14. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
Nozue T; Hattori H; Ishihara M; Iwasaki T; Hirano T; Kawashiri MA; Yamagishi M; Michishita I
Am J Cardiol; 2013 May; 111(10):1415-9. PubMed ID: 23433768
[TBL] [Abstract][Full Text] [Related]
15. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
Simonen P; Stenman UH; Gylling H
Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
[TBL] [Abstract][Full Text] [Related]
16. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
[TBL] [Abstract][Full Text] [Related]
17. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
Kwakernaak AJ; Lambert G; Slagman MC; Waanders F; Laverman GD; Petrides F; Dikkeschei BD; Navis G; Dullaart RP
Atherosclerosis; 2013 Feb; 226(2):459-65. PubMed ID: 23261172
[TBL] [Abstract][Full Text] [Related]
18. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease.
Hu D; Yang Y; Peng DQ
Int J Cardiol; 2017 Jan; 227():61-65. PubMed ID: 27846466
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
20. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment.
Werner C; Hoffmann MM; Winkler K; Böhm M; Laufs U
Vascul Pharmacol; 2014 Aug; 62(2):94-102. PubMed ID: 24685817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]